日本房颤成人患者阿哌沙班的群体药代动力学与药物基因组学研究
本研究纳入81例日本房颤患者,用NONMEM建立阿哌沙班一室一级吸收群体药代动力学模型,分析ABCB1、ABCG2、CYP3A5基因多态性及实验室数据对药代参数的影响。结果显示阿哌沙班口服清除率与肌酐清除率呈非线性关系,CYP3A5*1/*1和ABCG2 421C/C或C/A基因型患者清除率更高,ABCG2 421A/A与CYP3A5*3基因型及肾功能是影响药代动力学的内在因素。
要点
- 阿哌沙班口服清除率与肌酐清除率呈非线性关系,肾功能是重要影响因素。
- CYP3A5*1/*1基因型患者口服清除率较*1/*3或*3/*3高1.52倍。
- ABCG2 421C/C或C/A基因型患者口服清除率较421A/A高1.49倍。
核心结论
- ABCG2 421A/A和CYP3A5*3基因型及肾功能是影响阿哌沙班药代动力学的内在因素,可为精准用药提供参考。
研究设计与样本
- 研究纳入81例日本房颤患者,采集药物基因组学数据并按ABCB1、ABCG2和CYP3A5多态性分层。
- 采用一室一级吸收模型描述阿哌沙班药代动力学,使用NONMEM程序进行群体药代动力学分析。
主要发现
- 阿哌沙班口服清除率与肌酐清除率呈非线性关系。
- 典型患者(肌酐清除率70 ml min-1)且为CYP3A5*1/*1和ABCG2 421C/C或C/A基因型时,口服清除率群体均值为3.06 l h-1。
- 肌酐清除率取典型值时,CYP3A5*1/*1基因型患者口服清除率群体均值较CYP3A5*1/*3或*3/*3基因型高1.52倍。
- 肌酐清除率取典型值时,ABCG2 421C/C或C/A基因型患者口服清除率群体均值较ABCG2 421A/A基因型高1.49倍。
- 未发现影响阿哌沙班表观分布容积群体均值的协变量,表观分布容积群体均值估计为24.7 l。
临床怎么用
- 对携带ABCG2 421A/A或CYP3A5*3基因型且肾功能下降的房颤患者,可关注阿哌沙班暴露升高及相关不良反应风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: This study aimed to analyse the effects of genetic polymorphisms in drug transporters and metabolizing enzymes, and clinical laboratory data on the pharmacokinetic parameters of apixaban. METHODS: Data were collected from 81 Japanese patients with atrial fibrillation. Pharmacogenomic data were stratified by ABCB1, ABCG2 and CYP3A5 polymorphisms. The pharmacokinetic profile of apixaban was described by a one-compartment model with first-order absorption. Population pharmacokinetic analysis was conducted using a nonlinear mixed effect modelling (NONMEM™) program. RESULTS: The nonlinear relationship between oral clearance (CL/F) of apixaban and creatinine clearance (Ccr) was observed. The population mean of CL/F for a typical patient (Ccr value of 70 ml min-1 ) with the CYP3A5*1/*1 and ABCG2 421C/C or C/A genotypes was estimated to be 3.06 l h-1 . When Ccr values were set to the typical value, the population mean of CL/F was 1.52 times higher in patients with the CYP3A5*1/*1 genotype compared with patients with the CYP3A5*1/*3 or *3/*3 genotype, while the population mean of CL/F was 1.49 times higher in patients with the ABCG2 421C/C or C/A genotype compared with patients with the ABCG2 421A/A genotype. However, no covariates affected the population mean of the apparent volume of distribution (Vd/F) of apixaban. The population mean of Vd/F was estimated to be 24.7 l. CONCLUSION: The present study suggests that the ABCG2 421A/A and CYP3A5*3 genotypes and renal function are intrinsic factors affecting apixaban pharmacokinetics. These findings may provide useful information for precision medicine using apixaban, to avoid the risk of adverse reactions.
引用
- Ueshima S, Hira D, Kimura Y, et al. Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation. Br J Clin Pharmacol. 2018. PMID: 29457840. doi:10.1111/bcp.13561
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。